Tenax Therapeutics, Inc. TENX
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Tenax Therapeutics, Inc. (TENX) is a healthcare company listed in the US with a market value of about $74M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -66%.
About Tenax Therapeutics
Tenax Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 1 of the last 10 years in our data.
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — | — | — | — | — | $0 |
| Net income | -$53M | -$18M | -$8M | $11M | -$32M | -$10M | -$8M | -$14M | -$9M | -$44M |
| Free cash flow | — | — | — | -$11M | -$11M | -$9M | -$8M | -$6M | -$12M | -$16M |
| EPS (diluted) | $-1.34 | $-1.15 | $-31.04 | — | $-1.58 | $-0.95 | $-1.35 | $-9.04 | $-6.27 | $-31.24 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -45.9% | -16.7% | -75.6% | 379.5% | -570.1% | 158.1% | -171.4% | -46.3% | -81.9% | -242.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Tenax Therapeutics pay a dividend?
Not currently.
Is Tenax Therapeutics a good stock to buy?
We do not give buy or sell advice. Tenax Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.